Connect 2 Cleanrooms and Elis Cleanroom announce partnership
Connect 2 Cleanrooms (C2C) and Elis Cleanroom have signed a partnership agreement on 18 May to further strengthen the contamination control solution packages offered to their customers.
List view / Grid view
Connect 2 Cleanrooms (C2C) and Elis Cleanroom have signed a partnership agreement on 18 May to further strengthen the contamination control solution packages offered to their customers.
New research shows that there is hardly any robust data from studies available on blister packaging for nursing homes.
Research shows that the NHS continues to provide the optimum environment for the life sciences industry to deliver research.
GSK and Novartis found to have misled consumers with the packaging and pricing of their osteoarthritis pain treatment.
Pharmaceutical manufacturers and wholesale distributors could start losing billions of dollars because of faulty barcode scans.
The single-use bioprocessing systems market in Asia Pacific has witnessed an impressive rise and is expected to continue growing.
According to a recent article, drug companies are developing longer-acting, injectable HIV treatments.
A coalition of 43 attorneys general allege generic drug manufacturers colluded, overcharging US states and consumers billions.
The Cleanroom Technology Conference will take place at the National Conference Centre in Birmingham on 21-22 May.
Health Canada has published new guidance for manufacturers of higher-risk 3D-printed medical devices.
Gavi, the Vaccine Alliance has announced support for the expansion of a medical drone network into Ghana.
A new clinical trial will determine if monthly injections of anti-viral drugs are more effective at suppressing the HIV virus than daily pills.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
Chemspec Europe 2019 gathers impressive array of industry experts under one roof
A new drug for Huntington disease is found to be safe and lowers levels of the abnormal protein that causes the debilitating disease in patients.